

CO-DIAGNOSTICS CORONAVIRUS TEST IS LIKELY INEFFECTIVE – \$1 PRICE TARGET

February 18, 2020



RESEARCH SUMMARY

We're skeptical that Co-Diagnostics (CODX) new coronavirus test works, as news came out that the CDC's test may be flawed.

There is nowhere for CODX to test the coronavirus COVID-19 strain except China or a government lab in the US.

There is no committed institutional ownership of CODX and a major holder recently liquidated its entire position.

CODX' enterprise value to sales ratio is an eye-watering 608, making it one of the most overvalued medtech companies that we have ever seen.

CODX traded at below \$1 before the coronavirus hype happened. We predict it will sell-off towards that level as coronavirus news fades.

See follow-up CODX report *There Doesn't Appear To Be Any Real Interest In CODX - \$1 PT* on 3/17/20 [here](#).

See follow-up CODX info blog post on 3/23/20 [here](#).

We're skeptical that Co-Diagnostics (CODX) new coronavirus test works, as news came out that the CDC's test may be flawed.

There is nowhere for CODX to test the coronavirus COVID-19 strain except China or a government lab in the US.

There is no committed institutional ownership of CODX and a major holder recently liquidated its entire position.

CODX' enterprise value to sales ratio is an eye-watering 608, making it one of the most overvalued medtech companies that we have ever seen.

CODX traded at below \$1 before the coronavirus hype happened. We predict it will sell-off towards that level as coronavirus news fades.

See the full article on Seeking Alpha [here](#).



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap

equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC